Loading
Life sciences · Journal article
International Journal of Nutrology · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction: Age-related neurological disorders impose a growing clinical and public-health burden. Omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may influence neuronal membrane function, inflammatory resolution, oxidative balance, and synaptic integrity. Objective: It was to map current evidence on omega-3 fatty acids for the prevention and supportive management of neurological disorders in adults aged 60 years and older. Methods: A scoping-review approach was used to synthesize evidence from clinical trials, cohort and observational studies, systematic reviews, and mechanistic research identified in PubMed, Embase, Web of Science, Scopus, and the Cochrane Library. Evidence was organized by mechanism, population, neurological condition, outcome domain, and methodological feature. Because the purpose was evidence mapping rather than pooled effect estimation, no meta-analysis or statistical sample-size calculation was performed. Results: Mechanistic and observational evidence consistently supports biological plausibility and an association between higher omega-3 exposure and healthier cognitive ageing. Trial findings are heterogeneous. Benefits appear more plausible in cognitively normal individuals or those with early impairment, especially when baseline omega-3 status, dose, treatment duration, disease stage, and genetic susceptibility are considered. Evidence in established Alzheimer disease is generally weak, and Parkinson disease trials remain limited. Conclusions: Omega-3 fatty acids are promising components of multimodal neurological-health strategies, but they should not be presented as established stand-alone treatments. Future trials should be adequately powered, biomarker guided, longer in duration, and standardized in exposure and outcome measurement. Graphical Abstract